Lafutidine
- Generic Name
- Lafutidine
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29N3O4S
- CAS Number
- 118288-08-7
- Unique Ingredient Identifier
- 49S4O7ADLC
- Background
Lafutidine has been investigated in Peptic Ulcer, Community-acquired Pneumonia, and Gastroesophageal Reflux Disease (GERD).
- Indication
用于十二指肠溃疡和胃溃疡。
A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
Phase 1
Completed
- Conditions
- Gastric Ulcer
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT02759224
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of
Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 12
- Registration Number
- NCT02658864
The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT02581696
- Locations
- 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)Community-acquired Pneumonia
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
Phase 3
Completed
- Conditions
- Erosive Esophagitis
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 495
- Registration Number
- NCT01499368
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux
- Interventions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 325
- Registration Number
- NCT00229424
- Locations
- 🇯🇵
Tohoku University Hospital, 1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath